C
Capsida Biotherapeutics
Innovative gene therapies targeting CNS disorders with breakthrough neuronal transduction and liver detargeting
About Capsida Biotherapeutics
Capsida Biotherapeutics is a pioneering gene therapy platform company that is revolutionizing the medical field by creating a new class of targeted, non-invasive gene therapies. These therapies are designed to help patients suffering from debilitating and life-threatening disorders. The company's unique approach allows it to treat both rare and common diseases across all age groups.
Read full description
Capsida operates in the biotechnology market, serving a wide range of clients, including patients with both monogenic and polygenic diseases. Monogenic diseases are caused by a mutation in a single gene, while polygenic diseases are caused by mutations in multiple genes.
The company's business model is centered around the development and manufacturing of gene therapies. It does this by blending innovation with execution, creating customized therapies that selectively target specific organ systems while limiting exposure to non-targeted organs.
Capsida's revenue is generated through the development and sale of these gene therapies. The company is also built on a combination of in-house research and development (R&D) and industry partnerships, which further contribute to its revenue stream.
The company's unique selling point is its ability to engineer and screen capsids (protein shells of a virus) at an unrivaled scale. Using an automated, high-throughput biological screening method, Capsida's scientists can quickly identify optimal capsids to target tissues and cells in diseased organs.
In summary, Capsida Biotherapeutics is a leading player in the gene therapy market, providing innovative and targeted solutions for patients with life-threatening disorders.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Thousand Oaks, United States
- Employees
- 47
- Open positions
- 1
- Dealroom signal
- 58.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Capsida Biotherapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Feb 2023 | $0 | — | AbbVie | ↗ |
| SERIES AOther financing | Apr 2021 | $140M | $560M | Versant Ventures · Westlake Village BioPartners · AbbVie | — |
Growth signals
Latest recorded traffic for Capsida Biotherapeutics is 4.8K monthly website visits, up 65.5% over the last three months. Capsida Biotherapeutics's team declined 27.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Versant Ventures
Westlake Village BioPartners
AbbVie
Other known investors1 additional known investor
Caltech, California Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Capsida Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Capsida Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.